172 related articles for article (PubMed ID: 27185849)
1. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
Appel BE; Chen L; Buxton AB; Hutchison RE; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL
J Clin Oncol; 2016 Jul; 34(20):2372-9. PubMed ID: 27185849
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
3. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.
Dharmarajan KV; Friedman DL; Schwartz CL; Chen L; FitzGerald TJ; McCarten KM; Kessel SK; Iandoli M; Constine LS; Wolden SL
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):60-6. PubMed ID: 25542311
[TBL] [Abstract][Full Text] [Related]
4. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.
Appel BE; Chen L; Buxton A; Wolden SL; Hodgson DC; Nachman JB
Pediatr Blood Cancer; 2012 Dec; 59(7):1284-9. PubMed ID: 22847767
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
[TBL] [Abstract][Full Text] [Related]
6. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Nachman JB; Sposto R; Herzog P; Gilchrist GS; Wolden SL; Thomson J; Kadin ME; Pattengale P; Davis PC; Hutchinson RJ; White K;
J Clin Oncol; 2002 Sep; 20(18):3765-71. PubMed ID: 12228196
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group.
Parikh RR; Kelly KM; Hodgson DC; Hoppe BS; McCarten KM; Karolczuk K; Pei Q; Wu Y; Cho SY; Schwartz C; Cole PD; Roberts K
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):890-900. PubMed ID: 34767937
[TBL] [Abstract][Full Text] [Related]
10. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.
Tebbi CK; Mendenhall NP; London WB; Williams JL; Hutchison RE; Fitzgerald TJ; de Alarcón PA; Schwartz C; Chauvenet A
Pediatr Blood Cancer; 2012 Dec; 59(7):1259-65. PubMed ID: 22911615
[TBL] [Abstract][Full Text] [Related]
11. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
[TBL] [Abstract][Full Text] [Related]
13. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology.
Pellegrino B; Terrier-Lacombe MJ; Oberlin O; Leblanc T; Perel Y; Bertrand Y; Beard C; Edan C; Schmitt C; Plantaz D; Pacquement H; Vannier JP; Lambilliote C; Couillault G; Babin-Boilletot A; Thuret I; Demeocq F; Leverger G; Delsol G; Landman-Parker J;
J Clin Oncol; 2003 Aug; 21(15):2948-52. PubMed ID: 12885814
[TBL] [Abstract][Full Text] [Related]
15. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG; Castellino SM; Chen L; Pei Q; Voss SD; McCarten KM; Senn SL; Buxton AB; Bush R; Constine LS; Schwartz CL
Cancer; 2018 Aug; 124(15):3210-3219. PubMed ID: 29738613
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
17. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.
Fernández KS; Schwartz CL; Chen L; Constine LS; Chauvenet A; de Alarcón PA
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612375
[TBL] [Abstract][Full Text] [Related]
18. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
19. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study.
Tebbi CK; Mendenhall N; London WB; Williams JL; de Alarcon PA; Chauvenet AR;
Pediatr Blood Cancer; 2006 Feb; 46(2):198-202. PubMed ID: 16136581
[TBL] [Abstract][Full Text] [Related]
20. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
Parekh A; Keller FG; McCarten KM; Kessel S; Cho S; Pei Q; Wu Y; Castellino SM; Constine LS; Schwartz CL; Hodgson D; Kelly KM; Hoppe BS
Blood; 2022 Sep; 140(10):1086-1093. PubMed ID: 35763667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
